Market closed
Tenaya Therapeutics/$TNYA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Tenaya Therapeutics
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.
Ticker
$TNYA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
140
Website
TNYA Metrics
BasicAdvanced
$95M
-
-$1.44
2.35
-
Price and volume
Market cap
$95M
Beta
2.35
52-week high
$7.01
52-week low
$0.86
Average daily volume
2M
Financial strength
Current ratio
5.275
Quick ratio
4.912
Long term debt to equity
10.237
Total debt to equity
12.911
Management effectiveness
Return on assets (TTM)
-45.94%
Return on equity (TTM)
-84.49%
Valuation
Price to book
0.84
Price to tangible book (TTM)
0.84
Price to free cash flow (TTM)
-1.031
Growth
Earnings per share change (TTM)
-22.33%
3-year earnings per share growth (CAGR)
-42.27%
What the Analysts think about TNYA
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Tenaya Therapeutics stock.
TNYA Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
TNYA Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
TNYA News
AllArticlesVideos
Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative Medicine
GlobeNewsWire·2 weeks ago
Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated Milestones
GlobeNewsWire·1 month ago
Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Tenaya Therapeutics stock?
Tenaya Therapeutics (TNYA) has a market cap of $95M as of February 18, 2025.
What is the P/E ratio for Tenaya Therapeutics stock?
The price to earnings (P/E) ratio for Tenaya Therapeutics (TNYA) stock is 0 as of February 18, 2025.
Does Tenaya Therapeutics stock pay dividends?
No, Tenaya Therapeutics (TNYA) stock does not pay dividends to its shareholders as of February 18, 2025.
When is the next Tenaya Therapeutics dividend payment date?
Tenaya Therapeutics (TNYA) stock does not pay dividends to its shareholders.
What is the beta indicator for Tenaya Therapeutics?
Tenaya Therapeutics (TNYA) has a beta rating of 2.35. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.